mycophenolate sodium + cyclosporine

Mycophenolate sodium + cyclosporine is a combination immunosuppressive therapy used primarily in transplant medicine. This combination leverages the synergistic effects of both drugs to prevent organ rejection while managing side effects. ## Mechanism of Action Mycophenolate sodium is an enteric-coated formulation that delivers mycophenolic acid (MPA), the active metabolite. MPA works by inhibiting inosine monophosphate dehydrogenase (IMPDH), an enzyme crucial for de novo purine synthesis[8]. This inhibition particularly affects T and B lymphocytes, which rely heavily on this pathway for proliferation, resulting in potent immunosuppressive effects[8]. Cyclosporine functions by inhibiting calcineurin, thereby preventing T-cell activation and cytokine production. When combined with mycophenolate, there's a significant pharmacokinetic interaction: cyclosporine decreases MPA plasma concentrations by inhibiting the biliary excretion of MPA-glucuronide (MPAG) through the multidrug resistance-associated protein 2 (Mrp2) transporter[6]. ## Clinical Applications This combination is primarily used in: - Solid organ transplantation (kidney, liver, heart) to prevent graft rejection - Treatment of certain autoimmune conditions, though with limited efficacy in some cases like steroid-resistant focal segmental glomerulosclerosis (FSGS)[5] ## Pharmacokinetics When administered together, cyclosporine affects mycophenolate metabolism in several ways: - Decreases MPA exposure while increasing exposure to its metabolite MPAG[6] - Interferes with the biliary excretion of MPAG[6] - Can lead to rapid increases in MPA concentration when combined with other drugs like posaconazole[2] ## Efficacy and Safety The combination has shown significant efficacy in transplant settings: - In myeloablative sibling donor transplantation, the combination is well-tolerated[1] - Studies in dogs demonstrated synergism between the drugs, with stable graft-host tolerance in over 50% of subjects[7] Common adverse effects include: - Gastrointestinal symptoms (most frequent but generally mild)[5] - Potential for infections, particularly when combined with other immunosuppressants[4] - Hematological effects including thrombocytopenia[4] - Metabolic disturbances such as hypercholesterolemia and hyperglycemia[4] ## Dosing Considerations Due to the pharmacokinetic interactions between these drugs, careful monitoring is recommended: - MPA concentrations may not reach target levels initially but can increase significantly without dose changes[2] - Cyclosporine concentrations may increase significantly after several weeks of combined therapy, potentially requiring dose reduction[2] - Therapeutic drug monitoring is essential for optimizing therapy and minimizing toxicity[2][3] This combination represents an important therapeutic approach in transplant medicine, balancing efficacy in preventing rejection with manageable side effects through careful monitoring and dose adjustment.

Other names

cyclosporine + mycophenolic acidcyclosporin + mycophenolic acid